Marinova reporting growth for fucoidan products in US, Asia

Australian biotech firm Marinova has reported “exceptional” demand in the US and Asia for its fucoidans, bioactives from brown seaweed researchers believe could help to explain the health and longevity of the Japanese.While fucoidans were relatively new entrants to the US market, there was a “small but growing” body of science about their benefits, covering everything from anti-viral and anti-inflammatory effects to stem cell modulation, Marinova told

Marinova had also been “inundated with requests from Japan [where fucoidan is well-established] as they are concerned about their own seaweed supply due to possible radioactive contamination”, revealed business development manager Kevin Krail.

More info